Second line therapy in malignant pleural mesothelioma: A systematic review

Wieneke A Buikhuisen; Birgitta I Hiddinga; Paul Baas; Jan P van Meerbeeck

doi:10.1016/j.lungcan.2015.06.018

Second line therapy in malignant pleural mesothelioma: A systematic review

Lung Cancer. 2015 Sep;89(3):223-31. doi: 10.1016/j.lungcan.2015.06.018. Epub 2015 Jun 23.

Authors

Wieneke A Buikhuisen¹, Birgitta I Hiddinga², Paul Baas¹, Jan P van Meerbeeck³

Affiliations

¹ Thoraxoncologie, Nederlands Kanker Instituut, Amsterdam, The Netherlands.
² Thoraxoncologie, Universitair Ziekenhuis Antwerpen, Belgium.
³ Thoraxoncologie, Universitair Ziekenhuis Antwerpen, Belgium. Electronic address: p.baas@nki.nl.

PMID: 26162564
DOI: 10.1016/j.lungcan.2015.06.018

Abstract

After the implementation of standard first line chemotherapy with platinum and antifolates in pleural mesothelioma, patients are confronted with a need for second line treatment at relapse or progression. We conducted a systematic review of the literature for the activity, effectiveness and toxicity of second line treatment. The results are presented according to the class of drugs: chemotherapy and targeted or biological agent.

Keywords: Biological; Chemotherapy; Mesothelioma; Meta-analysis; Outcome; Second line; Targeted treatment; Treatment.

Publication types

Meta-Analysis
Review
Systematic Review

MeSH terms

Combined Modality Therapy
Humans
Lung Neoplasms / genetics
Lung Neoplasms / therapy*
Mesothelioma / genetics
Mesothelioma / therapy*
Mesothelioma, Malignant
Pleural Neoplasms / genetics
Pleural Neoplasms / therapy*
Retreatment
Treatment Outcome